tailieunhanh - Báo cáo y học: "ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. | Available online http content 11 6 R163 Research article ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis a systematic review of the literature Stefano Alivernini Antonella Laria Elisa Gremese Angelo Zoli and Gianfranco Ferraccioli Division of Rheumatology School of Medicine Catholic University of the Sacred Heart Largo F Vito 1 00168 Rome Italy Corresponding author Gianfranco Ferraccioli Received 15 Jul 2009 Revisions requested 20 Aug 2009 Revisions received 24 Oct 2009 Accepted 3 Nov 2009 Published 3 Nov 2009 Arthritis Research Therapy 2009 11 R163 doi 86 ar2848 This article is online at http content 11 6 R163 2009 Alivernini et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction The aim of our analysis was to compare the gaining of a major response disease activity score DAS remission or American College of Rheumatology 70 improvement criteria ACR70 by switching between all the available biological therapies in rheumatoid arthritis. Methods A systematic review was performed including studies published before December 2008 in which a second biological agent was used and clinical outcomes were evaluated after a first biological failure. Results Nine articles were included. Switching from etanercept and or infliximab to adalimumab is effective with an ACR70 response ranging from 5 to 33 . Rituximab may be slightly more effective than switching to a second anti-tumor necrosis factor-alpha anti-TNFa reaching an ACR70 or DAS remission response in 12 and 9 respectively. Clinical trials confirmed the efficacy in switching to .